Methylene blue treatment for cytokine release syndrome-associated vasoplegia following a renal transplant with rATG infusion: A case report and literature review

Denny,John  T.; Burr,Andrew  T.; Balzer,Fred; Tse,James  T.; Denny,Julia  E.; Chyu,Darrick

doi:10.3892/etm.2015.2349

Methylene blue treatment for cytokine release syndrome-associated vasoplegia following a renal transplant with rATG infusion: A case report and literature review

Authors:
- John T. Denny
- Andrew T. Burr
- Fred Balzer
- James T. Tse
- Julia E. Denny
- Darrick Chyu
View Affiliations

Affiliations: Department of Anesthesia, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ 08901, USA, Virtua Memorial Hospital, Department of Anesthesia, Mount Holly, NJ 08060, USA, Department of Anesthesia, New York University Medical Center, New York, NY 10016, USA
Published online on: March 12, 2015 https://doi.org/10.3892/etm.2015.2349
Pages: 1915-1920

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Rabbit anti‑thymocyte globulin (rATG) is an infusion of polyclonal rabbit‑derived antibodies against human thymocyte markers, which can be used to prevent and treat acute rejection following organ transplantation. However, the product monograph issued by the manufacturer (Sanofi Canada) reports that serious immune‑mediated reactions have been observed following the use of rATG, consisting of anaphylaxis or severe cytokine release syndrome (CRS), which is a form of vasoplegic syndrome (VS), in which distributive shock occurs refractory to norepinephrine (NE) and vasopressin (VP). Severe infusion‑associated reactions are consistent with CRS and can cause serious cardiac or respiratory problems, or in certain cases, mortality. CRS is a form of systemic inflammatory response syndrome (SIRS). In SIRS, the substantial activation of endothelial inducible nitric oxide synthase (iNOS) and smooth muscle guanylate cyclase (GC) is observed, which can produce severe hypotension that is unresponsive to conventional vasopressors. Methylene blue (MB) is a direct inhibitor of iNOS and GC and has been used as an effective treatment for VS following cardiothoracic surgery. In the present study, the successful use of MB as a rescue therapy for CRS in a patient receiving rATG following a renal transplant was reported. Following an uneventful cadaveric kidney transplant involving the intravenous (IV) administration of rATG for the induction of immunological tolerance, the patient became markedly hypotensive and tachycardic. The patient required high doses of VP and NE infusions. Following the protocol described for treating refractory VS in post‑cardiac surgery patients, the decision was made to initiate the patient on an IV MB infusion. This treatment protocol was shown to improve the hemodynamic status of the patient, which enabled the withdrawal of vasopressors and suggests an important role for methylene blue in the management of refractory VS.

View Figures

View References

1	Teachey DT, Rheingold SR, Maude SL, et al: Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 121:5154–5157. 2013. View Article : Google Scholar : PubMed/NCBI
2	Sanofi Canada: Thymoglobulin® (Anti-thymocyte globulin [rabbit]) product monograph. http://products.sanofi.ca/en/thymoglobulin.pdfJan 25–2015
3	Mahmud N, Klipa D and Ahsan N: Antibody immunosuppressive therapy in solid-organ transplant: Part I. MAbs. 2:148–156. 2010. View Article : Google Scholar : PubMed/NCBI
4	Shanmugam G: Vasoplegic syndrome - the role of methylene blue. Eur J Cardiothorac Surg. 28:705–710. 2005. View Article : Google Scholar : PubMed/NCBI
5	Landry DW and Oliver JA: The pathogenesis of vasodilatory shock. N Engl J Med. 345:588–595. 2001. View Article : Google Scholar : PubMed/NCBI
6	Friedrich M, Bräuer A, Tirilomis T, Lotfi S, Mielck F and Busch T: Methylene blue administration in severe systemic inflammatory response syndrome (SIRS) after thoracic surgery. Ann Thorac Cardiovasc Surg. 8:306–310. 2002.PubMed/NCBI
7	Stawicki SP, Sims C, Sarani B, Grossman MD and Gracias VH: Methylene blue and vasoplegia: who, when, and how? Mini Rev Med Chem. 8:472–490. 2008. View Article : Google Scholar : PubMed/NCBI
8	Argenziano M, Chen JM, Cullinane S, et al: Arginine vasopressin in the management of vasodilatory hypotension after cardiac transplantation. J Heart Lung Transplant. 18:814–817. 1999. View Article : Google Scholar : PubMed/NCBI
9	Taylor KM: SIRS - the systemic inflammatory response syndrome after cardiac operations. Ann Thorac Surg. 61:1607–1608. 1996. View Article : Google Scholar : PubMed/NCBI
10	Downing SW and Edmunds LH Jr: Release of vasoactive substances during cardiopulmonary bypass. Ann Thorac Surg. 54:1236–1243. 1992. View Article : Google Scholar : PubMed/NCBI
11	Flynn BC and Sladen RN: The use of methylene blue for vasodilatory shock in a pediatric lung transplant patient. J Cardiothorac Vasc Anesth. 23:529–530. 2009. View Article : Google Scholar : PubMed/NCBI
12	Levin RL, Degrange MA, Bruno GF, et al: Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Ann Thorac Surg. 77:496–499. 2004. View Article : Google Scholar : PubMed/NCBI
13	Beasley D and McGuiggin M: Interleukin 1 activates soluble guanylate cyclase in human vascular smooth muscle cells through a novel nitric oxide-independent pathway. J Exp Med. 179:71–80. 1994. View Article : Google Scholar : PubMed/NCBI
14	Mekontso-Dessap A, Houël R, Soustelle C, Kirsch M, Thebért D and Loisance DY: Risk factors for post-cardiopulmonary bypass vasoplegia in patients with preserved left ventricular function. Ann Thorac Surg. 71:1428–1432. 2001. View Article : Google Scholar : PubMed/NCBI
15	Robin JK, Oliver JA and Landry DW: Vasopressin deficiency in the syndrome of irreversible shock. J Trauma. 54(Suppl): S149–S154. 2003.PubMed/NCBI
16	Boyle EM Jr..Pohlman TH, Johnson MC and Verrier ED: Endothelial cell injury in cardiovascular surgery: the systemic inflammatory response. Ann Thorac Surg. 63:277–284. 1997.PubMed/NCBI
17	Kwok ES and Howes D: Use of methylene blue in sepsis: A systematic review. J Intensive Care Med. 21:359–363. 2006. View Article : Google Scholar : PubMed/NCBI
18	Cauwels A, Janssen B, Buys E, Sips P and Brouckaert P: Anaphylactic shock depends on PI3K and eNOS-derived NO. J Clin Invest. 116:2244–2251. 2006. View Article : Google Scholar : PubMed/NCBI
19	Montrucchio G, Alloatti G and Camussi G: Role of platelet-activating factor in cardiovascular pathophysiology. Physiol Rev. 80:1669–1699. 2000.PubMed/NCBI
20	Neugut AI, Ghatak AT and Miller RL: Anaphylaxis in the United States: an investigation into its epidemiology. Arch Intern Med. 161:15–21. 2001. View Article : Google Scholar : PubMed/NCBI
21	Gomes WJ, Carvalho AC, Palma JH, et al: Vasoplegic syndrome after open heart surgery. J Cardiovasc Surg (Torino). 39:619–623. 1998.PubMed/NCBI
22	Schulz R, Nava E and Moncada S: Induction and potential biological relevance of a Ca(2+)-independent nitric oxide synthase in the myocardium. Br J Pharmacol. 105:575–580. 1992. View Article : Google Scholar : PubMed/NCBI
23	Cremer J, Martin M, Redl H, et al: Systemic inflammatory response syndrome after cardiac operations. Ann Thorac Surg. 61:1714–1720. 1996. View Article : Google Scholar : PubMed/NCBI
24	Brown SG: Cardiovascular aspects of anaphylaxis: implications for treatment and diagnosis. Curr Opin Allergy Clin Immunol. 5:359–364. 2005. View Article : Google Scholar : PubMed/NCBI
25	Kemp SF and Lockey RF: Anaphylaxis: a review of causes and mechanisms. J Allergy Clin Immunol. 110:341–348. 2002. View Article : Google Scholar : PubMed/NCBI
26	Takakura K, Mizogami M and Fukuda S: Protamine sulfate causes endothelium-independent vasorelaxation via inducible nitric oxide synthase pathway. Can J Anaesth. 53:162–167. 2006. View Article : Google Scholar : PubMed/NCBI
27	Viaro F, Dalio MB and Evora PR: Catastrophic cardiovascular adverse reactions to protamine are nitric oxide/cyclic guanosine monophosphate dependent and endothelium mediated: should methylene blue be the treatment of choice? Chest. 122:1061–1066. 2002. View Article : Google Scholar : PubMed/NCBI
28	Donati A, Conti G, Loggi S, et al: Does methylene blue administration to septic shock patients affect vascular permeability and blood volume? Crit Care Med. 30:2271–2277. 2002. View Article : Google Scholar : PubMed/NCBI
29	Thiemermann C, Szabó C, Mitchell JA and Vane JR: Vascular hyporeactivity to vasoconstrictor agents and hemodynamic decompensation in hemorrhagic shock is mediated by nitric oxide. In: Proc Natl Acad Sci USA. 90. pp. 267–271. 1993; View Article : Google Scholar : PubMed/NCBI
30	Peer G, Itzhakov E, Wollman Y, et al: Methylene blue, a nitric oxide inhibitor, prevents haemodialysis hypotension. Nephrol Dial Transplant. 16:1436–1441. 2001. View Article : Google Scholar : PubMed/NCBI
31	Guttmann RD, Caudrelier P, Alberici G and Touraine JL: Pharmacokinetics, foreign protein immune response, cytokine release, and lymphocyte subsets in patients receiving thymoglobuline and immunosuppression. In: Transplant Proc. 29. pp. 24S–26S. 1997; View Article : Google Scholar : PubMed/NCBI
32	Jeyarajah DR and Thistlethwaite JR Jr.: General aspects of cytokine-release syndrome: timing and incidence of symptoms. In: Transplant Proc. 25(Suppl 1): pp. 16–20. 1993; PubMed/NCBI
33	Radhakrishnan J and Cohen DJ: Cytokine-release syndrome: general risk-factor modification - preparation of high-risk patients for use of OKT3. In: Transplant Proc. 25(Suppl 1): pp. 60–62. 1993; PubMed/NCBI
34	Rosenzweig EB, Starc TJ, Chen JM, et al: Intravenous arginine-vasopressin in children with vasodilatory shock after cardiac surgery. Circulation. 100(Suppl): II182–II186. 1999.PubMed/NCBI
35	Torgersen C, Dünser MW, Wenzel V, et al: Comparing two different arginine vasopressin doses in advanced vasodilatory shock: a randomized, controlled, open-label trial. Intensive Care Med. 36:57–65. 2010. View Article : Google Scholar : PubMed/NCBI
36	Dellinger RP, Levy MM, Rhodes A, et al: Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup: Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Critical Care Med. 41:580–637. 2013. View Article : Google Scholar
37	Alexander JH, Reynolds HR, Stebbins AL, et al: TRIUMPH Investigators: Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA. 297:1657–1666. 2007. View Article : Google Scholar : PubMed/NCBI
38	Grubb KJ, Kennedy JL, Bergin JD, Groves DS and Kern JA: The role of methylene blue in serotonin syndrome following cardiac transplantation: a case report and review of the literature. J Thorac Cardiovasc Surg. 144:e113–e116. 2012. View Article : Google Scholar : PubMed/NCBI
39	Licker M, Diaper J, Cartier V, et al: Clinical review: management of weaning from cardiopulmonary bypass after cardiac surgery. Ann Card Anaesth. 15:206–223. 2012. View Article : Google Scholar : PubMed/NCBI
40	Sloan EP, Koenigsberg MD, Philbin NB and Gao W: DCLHb Traumatic Hemorrhagic Shock Study Group; European HOST Investigators: Diaspirin cross-linked hemoglobin infusion did not influence base deficit and lactic acid levels in two clinical trials of traumatic hemorrhagic shock patient resuscitation. J Trauma. 68:1158–1171. 2010. View Article : Google Scholar : PubMed/NCBI
41	Leyh RG, Kofidis T, Strüber M, et al: Methylene blue: the drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass? J Thorac Cardiovasc Surg. 125:1426–1431. 2003. View Article : Google Scholar : PubMed/NCBI
42	Fischer GW and Levin MA: Vasoplegia during cardiac surgery: current concepts and management. Semin Thorac Cardiovasc Surg. 22:140–144. 2010. View Article : Google Scholar : PubMed/NCBI